Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

NCT04453137 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

567

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL: Adalimumab originator
BIOLOGICAL: Adalimumab biosimilar

Sponsor

Alvotech Swiss AG